Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/14/2009 First Published: 11/1/2001


1.		Phase III Randomized Study of Adjuvant Isotretinoin With or Without Monoclonal Antibody Ch14.18, Interleukin-2, and Sargramostim (GM-CSF) in Patients With Neuroblastoma Who Have Completed Myeloablative Therapy and Autologous Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Temporarily closed				30 and under at diagnosis				NCI				COG-ANBL0032 ANBL0032, COG-P9842, NCT00026312

Last Modified: 3/26/2007


2.		Phase II Study of MOAB Ch14.18 with GM-CSF for Recurrent Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				under 21				NCI				POG-9347

Last Modified: 12/11/2008 First Published: 6/1/1994


3.		Phase I Study of Monoclonal Antibody Ch14.18 Combined With Sargramostim (GM-CSF) and Interleukin-2 After Autologous Bone Marrow or Peripheral Blood Stem Cell Rescue in Children With Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				21 and under				NCI				COG-A0935A CCG-0935, CCG-0935A, NCT00005576

Last Modified: 9/1/1997


4.		Phase I Study of Monoclonal Antibodies Ch14.18 and R24 with IL-2 for Melanoma, Small Cell Lung Carcinoma, Soft Tissue Sarcoma, and Other GD2- and GD3-Positive Tumors (Summary Last Modified 09/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				WCCC-CO-9391 NCI-B94-0002, B94-0002

Last Modified: 6/1/1993


5.		Phase Ia/Ib Study of Chimeric Monoclonal Anti-GD2 Antibody 14.18 in Patients with Metastatic Melanoma (Summary Last Modified 06/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over								UAB-185 NCI-B89-0005, B89-0005

Last Modified: 11/1/1994


6.		Phase I Study of Melanoma-Reactive Chimeric Anti-GD-2 Monoclonal Antibody 14.18 plus IL-2 for Refractory Metastatic Melanoma (Summary Last Modified 11/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over								WCCC-CO-9097 NCI-B90-0014, B90-0014

Last Modified: 5/1/1995


7.		Phase I Study of Chimeric MOAB 14.18 plus GM-CSF for Metastatic Melanoma (Summary Last Modified 05/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 to physiologic 70								MDA-DM-90102 NCI-B93-0009, B93-0009

Last Modified: 3/1/1997


8.		Phase I Pilot Study of Chimeric MOAB 14.18 for Refractory Small Cell Lung Cancer (Summary Last Modified 03/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				MSKCC-93049A4 NCI-B93-0001, B93-0001

Select All on One Page